Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Wouters, M.W.J.M.

Refine Results

Resource Type

Availability

Creation Date

Show more

Topic

Show more

Author

Show more

Language

Search results

  • RSS Feed
(1 - 20 of 204)

Pages

A prediction model for response to immune checkpoint inhibition in advanced melanoma
BRAF/MEK inhibitor rechallenge in advanced melanoma patients
Does size matter?
Does centralization of radical prostatectomy reduce the incidence of postoperative urinary incontinence
The impact on health-related quality of a stoma or poor functional outcomes after rectal cancer surgery in Dutch patients
Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort
Patient perspectives on consequences of resection for colorectal cancer
Real-world outcomes of ipilimumab plus nivolumab combination therapy in a nationwide cohort of advanced melanoma patients in the Netherlands
A survival tree of advanced melanoma patients with brain metastases treated with immune checkpoint inhibitors
Textbook outcome as a composite outcome measure to compare hospital performances regarding cytoreductive surgery for ovarian cancer
Use of hospital care among Dutch diabetes patients
Healthcare expenditure and technology use in pediatric diabetes care
Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies
Adjuvant treatment of in-transit melanoma
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
Using existing clinical information models for Dutch quality registries to reuse data and follow COUMT paradigm
Population mortality in advanced melanoma patients with and without response and progression
Computed tomography-based preoperative muscle measurements as prognostic factors for anastomotic leakage following oncological sigmoid and rectal resections
Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC
Adjuvant BRAF-MEK inhibitors versus Anti PD-1 Therapy in stage III melanoma

Pages